169 related articles for article (PubMed ID: 38157684)
1. An update on ICU outcomes in patients after CAR T therapy: A four-year tertiary UK centre experience.
Scourfield L; Pirani T; Singh N; Saha R; Kuhnl A; Sanderson R; Metaxa V
J Crit Care; 2024 Apr; 80():154511. PubMed ID: 38157684
[No Abstract] [Full Text] [Related]
2. Critical care utilisation for patients receiving chimeric antigen receptor (CAR) T cell therapy in the UK.
Pirani T; Wilson A; Brealey D; Low R; O'Neill S; Le J; Jhanji S; Bangash MN; Mathew A; Wright C; Latif AL; Irvine D; Kasipandian V; Singh N; Saha R; Metaxa V
Br J Anaesth; 2024 May; 132(5):1004-1006. PubMed ID: 38521658
[No Abstract] [Full Text] [Related]
3. Severe presentations and high mortality from SARS-CoV-2 in patients undergoing chimeric antigen receptor (CAR-T) therapy: a UK NCCP analysis.
Cheok KPL; Kirkwood AA; Menne T; Tholouli E; Chaganti S; Mathew A; Uttenthal B; Russell J; Irvine D; Johnson R; Nicholson E; Bazin J; Townsend W; Kuhnl A; O'Reilly M; Sanderson R; Patel A; Roddie C
Leuk Lymphoma; 2022 Aug; 63(8):1980-1984. PubMed ID: 35481791
[No Abstract] [Full Text] [Related]
4. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
Chen L; Chen F; Niu H; Li J; Pu Y; Yang C; Wang Y; Huang R; Li K; Lei Y; Huang Y
Front Immunol; 2022; 13():871661. PubMed ID: 35911706
[TBL] [Abstract][Full Text] [Related]
5. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities.
Gutierrez C; Brown ART; Herr MM; Kadri SS; Hill B; Rajendram P; Duggal A; Turtle CJ; Patel K; Lin Y; May HP; Gallo de Moraes A; Maus MV; Frigault MJ; Brudno JN; Athale J; Shah NN; Kochenderfer JN; Dharshan A; Beitinjaneh A; Arias AS; McEvoy C; Mead E; Stephens RS; Nates JL; Neelapu SS; Pastores SM
J Crit Care; 2020 Aug; 58():58-64. PubMed ID: 32361219
[TBL] [Abstract][Full Text] [Related]
6. [CAR-T cell therapy - personalized cellular immunotherapy in 2022].
Niebling J; Bethge W; Lengerke C
Dtsch Med Wochenschr; 2022 Nov; 147(23):1552-1564. PubMed ID: 36384157
[TBL] [Abstract][Full Text] [Related]
7. Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature.
Major A; Collins J; Craney C; Heitman AK; Bauer E; Zerante E; Stock W; Bishop MR; Jasielec J
Leuk Lymphoma; 2021 Jul; 62(7):1765-1769. PubMed ID: 33559517
[No Abstract] [Full Text] [Related]
8. Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells.
Karschnia P; Miller KC; Yee AJ; Rejeski K; Johnson PC; Raje N; Frigault MJ; Dietrich J
Blood; 2023 Oct; 142(14):1243-1248. PubMed ID: 37471607
[No Abstract] [Full Text] [Related]
9. Immunotherapy Using Chimeric Antigen Receptor-Engineered T Cells: A Novel Cellular Therapy with Important Implications for the Clinical Laboratory.
Thibodeaux SR; Milone MC
Clin Chem; 2019 Apr; 65(4):519-529. PubMed ID: 30593467
[TBL] [Abstract][Full Text] [Related]
10. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
[TBL] [Abstract][Full Text] [Related]
11. Safer CAR T-Cell Therapy.
Abbasi J
JAMA; 2019 Jun; 321(22):2155. PubMed ID: 31184718
[No Abstract] [Full Text] [Related]
12. CAR T cells - what have we learnt?
Nat Rev Clin Oncol; 2017 Dec; 15(1):1. PubMed ID: 29242589
[No Abstract] [Full Text] [Related]
13. CAR-T cell therapy in paediatric acute lymphoblastic leukaemia - past, present and future.
Rogosic S; Ghorashian S
Br J Haematol; 2020 Nov; 191(4):617-626. PubMed ID: 33190266
[TBL] [Abstract][Full Text] [Related]
14. Chimeric Antigen Receptor (CAR) T-Cell Therapy.
Pagel JM; West HJ
JAMA Oncol; 2017 Nov; 3(11):1595. PubMed ID: 28880983
[No Abstract] [Full Text] [Related]
15. ASCO releases guideline on CAR T-cell therapy: A multidisciplinary team's recommendations help in the recognition, workup, evaluation, and management of the most common chimeric antigen receptor (CAR) T-cell-related toxicities: A multidisciplinary team's recommendations help in the recognition, workup, evaluation, and management of the most common chimeric antigen receptor (CAR) T-cell-related toxicities.
O'Rourke K
Cancer; 2022 Feb; 128(3):429-430. PubMed ID: 35050523
[No Abstract] [Full Text] [Related]
16. Preclinical scenario of targeting myocardial fibrosis with chimeric antigen receptor (CAR) immunotherapy.
Ferrer-Curriu G; Soler-Botija C; Charvatova S; Motais B; Roura S; Galvez-Monton C; Monguió-Tortajada M; Iborra-Egea O; Emdin M; Lupón J; Aimo A; Bagó JR; Bayés-Genís A
Biomed Pharmacother; 2023 Feb; 158():114061. PubMed ID: 36495661
[TBL] [Abstract][Full Text] [Related]
17. Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy.
Ghassemi S; Milone MC
J Vis Exp; 2019 Dec; (154):. PubMed ID: 31904011
[TBL] [Abstract][Full Text] [Related]
18. CT Demonstration of Local Cytokine-Release Syndrome Involving the Head and Neck Following Chimeric Antigen Receptor T Cell Infusion Therapy.
Ko JS; Lee JH; Yoon DH; Suh CH; Chung SR; Choi YJ; Baek JH
Korean J Radiol; 2024 Apr; 25(4):399-402. PubMed ID: 38528698
[No Abstract] [Full Text] [Related]
19. Decentralised, point-of-care CAR-T for multiple myeloma.
Anguille S; Krekelbergh L
Lancet Oncol; 2023 Aug; 24(8):828-830. PubMed ID: 37414061
[No Abstract] [Full Text] [Related]
20. [Hematological toxicity and risk factors in relapsed/refractory multiple myeloma patients after CAR-T therapy].
Zhao TT; Ge J; Zhu H; Ma RB; Li CY; Wan CY; Wang Y; Xu KL; Li ZY
Zhonghua Xue Ye Xue Za Zhi; 2022 Oct; 43(10):858-860. PubMed ID: 36709201
[No Abstract] [Full Text] [Related]
[Next] [New Search]